Lifecore Biomedical (LFCR) Stock: Buy, Sell, or Hold?
LFCR - Lifecore Biomedical, Inc. Common Stock
$6.37
0.00 (0.00%)
â˛
5d:
-1.09%
30d:
+44.77%
90d:
+47.11%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When LFCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: LFCR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: LFCR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: LFCR is currently trading at $6.37, which is considered slightly high relative to its 30-day fair value range of $4.31 to $6.52.
Technical Outlook: Technically, LFCR is in a uptrend. The price is currently testing key support at $6.36. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: LFCR scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LFCR is in a uptrend. The price is currently testing key support at $6.36. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: LFCR scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$4.31 -
$6.52
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
36.8%
All Signals
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($6.28)
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.31 -
$6.52
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$6.36
Resistance Level
$6.48
Current Trend
Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.69
Wall Street Target
$6.28
(-1.4%)
Revenue Growth (YoY)
-3.8%
Profit Margin
-23.8%
Share & Embed Analysis
Last updated: October 23, 2026 4:37 AM ET
Data refreshes hourly during market hours. Next update: 5:37 AM
Data refreshes hourly during market hours. Next update: 5:37 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LFCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
29 analysts |
$207 | 60 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 49 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 43 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 59 HOLD |
